Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2024 | Advances in managing ARIA in patients with Alzheimer’s disease treated with donanemab

Suzanne Schindler • 12 Aug 2024
CTAD 2024
Alzheimer’s Disease Dementia Antibodies Donanemab

Suzanne Schindler, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, discusses a presentation focused on decreasing the rates of amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease treated with donanemab. Dr Schindler highlights that the slow up-titration of donanemab can be adopted by clinicians to provide safer anti-amyloid treatments for patients. This interview took place at the 2024 CTAD congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Suzanne Schindler

The development of plasma biomarker clocks to predict AD symptom onset 4:51
The development of plasma biomarker clocks to predict AD symptom onset
Suzanne Schindler • 9 Dec 2025
The development and use of biomarkers for combination therapy in Alzheimer’s disease 4:53
The development and use of biomarkers for combination therapy in Alzheimer’s disease
Suzanne Schindler • 9 Dec 2025
Advances in fluid biomarker research for the treatment of neurodegenerative diseases 4:48
Advances in fluid biomarker research for the treatment of neurodegenerative diseases
Suzanne Schindler • 12 Nov 2024
Swedish BioFINDER-2: investigating the diagnostic accuracy of p-tau217 for Alzheimer’s disease 1:07
Swedish BioFINDER-2: investigating the diagnostic accuracy of p-tau217 for Alzheimer’s disease
Suzanne Schindler • 12 Aug 2024

Related Videos

Shingles vaccination is associated with a reduced risk of new dementia diagnoses 4:49
Shingles vaccination is associated with a reduced risk of new dementia diagnoses
Pascal Geldsetzer • 8 Dec 2025
Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases 3:54
Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases
Muhaison Ibrahim • 10 Dec 2025
Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk 6:35
Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk
Muhaison Ibrahim • 10 Dec 2025
The potential clinical utility of the novel p-tau205 biomarker in Alzheimer’s disease 3:00
The potential clinical utility of the novel p-tau205 biomarker in Alzheimer’s disease
Gemma Salvadó • 12 Dec 2025
The content of VJDementia is intended for healthcare professionals